| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (NCT05242471) | Janssen Research & Development, LLC | 2022-07-22 |
| A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) (NCT05394805) | AbbVie | 2022-06-29 |
| The MOTOR-CD Trial (NCT05363930) | Asian Institute of Gastroenterology, India | 2022-05-07 |
| A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease (NCT05028946) | Tiziana Life Sciences LTD | 2022-05-01 |
| Stem Cells for the Treatment of Pouchitis (NCT05578508) | The Cleveland Clinic | 2022-04-01 |
| A Study of Ustekinumab Treatment in Children With Crohn's Disease (NCT05242458) | Janssen Research & Development, LLC | 2022-03-21 |
| Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease (NCT05049525) | Montreal Heart Institute | 2022-02-22 |
| A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (NCT05068284) | AbbVie | 2022-01-31 |
| A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease (NCT05626023) | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 2022-01-30 |
| A Survey of Darvadstrocel in People With Crohn's Disease (NCT05113095) | Takeda | 2021-11-30 |
| Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency (NCT05078879) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-16 |
| Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 (NCT05088369) | Syneos Health | 2021-11-11 |
| Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease (NCT05057273) | NImmune Biopharma | 2021-11-01 |
| Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II) (NCT04847739) | Avobis Bio, LLC | 2021-09-13 |
| Synbiotics and Post-op Crohn's Disease (NCT04804046) | University of Alberta | 2021-07-15 |
| A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease (NCT04701411) | Takeda | 2021-06-30 |
| A Study of CDPATH™ to Help Manage and Treat Crohn's Disease (NCT04809363) | Takeda | 2021-06-25 |
| A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (NCT04738942) | Takeda | 2021-06-04 |
| A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease (NCT04643483) | UCB Biopharma SRL | 2021-06-01 |
| Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's (NCT04073472) | The Cleveland Clinic | 2021-06-01 |
| A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD) (NCT05596422) | Takeda | 2021-05-27 |
| A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (NCT04844606) | Eli Lilly and Company | 2021-05-26 |
| Diet in Pediatric Crohn´s Disease Treated With Biologics (NCT05034458) | Hospital Italiano de Buenos Aires | 2021-05-14 |
| Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease (NCT03870334) | NImmune Biopharma | 2021-05-05 |
| Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease (NCT05867784) | Second Affiliated Hospital of Wenzhou Medical University | 2021-04-30 |
| Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography (NCT04650867) | University of Erlangen-Nürnberg Medical School | 2021-03-22 |
| Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease (NCT03648398) | Central Hospital, Nancy, France | 2021-01-29 |
| Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease (NCT04713631) | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 2021-01-21 |
| A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula (NCT04118088) | Takeda | 2020-12-22 |
| USTekinumab in Fistulising Perianal Crohn's Disease (USTAP) (NCT04496063) | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 2020-11-16 |
| A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease. (NCT04939337) | Jinling Hospital, China | 2020-11-12 |
| Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency (NCT04276636) | Second Affiliated Hospital of Wenzhou Medical University | 2020-10-01 |
| Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With Vitamin D Deficiency (NCT04308850) | Second Affiliated Hospital of Wenzhou Medical University | 2020-10-01 |
| Pregnancy and Inflammatory Bowel Disease (NCT07377188) | Centre Hospitalier Universitaire, Amiens | 2020-09-18 |
| Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU (NCT06031038) | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | 2020-09-15 |
| Predicting Medication Response for Autoimmune Disease (NCT04995783) | Coral Genomics, Inc. | 2020-09-01 |
| ENhanced Recovery in CHildren Undergoing Surgery (NCT04060303) | Northwestern University | 2020-07-01 |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (NCT04232553) | Eli Lilly and Company | 2020-06-22 |
| A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (NCT04163016) | UCB Biopharma SRL | 2020-06-19 |
| A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease (NCT04254783) | AbbVie | 2020-05-27 |
| The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD) (NCT04290156) | University of Pecs | 2020-04-01 |
| Mesenteric SParIng Versus Central mesenterectomY in Ileocolic Resection for Terminal Ileitis in Crohn's Disease (NCT04538638) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2020-03-01 |
| Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation (NCT03850509) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-02-25 |
| MICISPORT Survey : Questionnaire (NCT04297566) | University Hospital, Montpellier | 2020-02-20 |
| A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (NCT04173273) | Pfizer | 2020-01-06 |
| Open-label Extension Study of Brazikumab in Crohn's Disease (NCT03961815) | AstraZeneca | 2020-01-06 |
| Artificial Intelligence-Based Classification and Prognostic Prediction in Small Bowel Crohn's Disease (NCT07757217) | Shanghai 10th People's Hospital | 2020-01-01 |
| AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) (NCT02677350) | Joshua M Hare | 2019-12-01 |
| Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula (NCT04075825) | Takeda | 2019-11-05 |
| Autologous Transplant Targeted Against Crohn's (NCT04154735) | Northwestern University | 2019-11-01 |
| Ustekinumab Real World Evidence Study (NCT07748338) | University Hospital Southampton NHS Foundation Trust | 2019-10-30 |
| CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) (NCT03945019) | Celltrion | 2019-10-28 |
| Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (NCT04131504) | Children's Hospital Medical Center, Cincinnati | 2019-10-16 |
| Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) (NCT04852666) | University of North Carolina, Chapel Hill | 2019-07-25 |
| A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (NCT03926130) | Eli Lilly and Company | 2019-07-23 |
| Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease (NCT03890445) | Sandoz | 2019-06-24 |
| Cell Surface Marker Expression in Autoimmune Diseases (NCT03757065) | Alpine Immune Sciences, Inc. | 2019-06-12 |
| A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (NCT03677648) | Reistone Biopharma Company Limited | 2019-05-14 |
| A Study of E6011 in Participants With Active Crohn's Disease (NCT03733314) | EA Pharma Co., Ltd. | 2019-04-25 |
| Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis) (NCT03884439) | Pfizer | 2019-03-18 |
| Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (NCT03627091) | Shire | 2019-02-06 |
| A Study on the Associations of Toll-like Receptor 5 Gene Polymorphisms With Crohn's Disease in Chinese Patients (NCT07035678) | Second Affiliated Hospital of Wenzhou Medical University | 2019-01-01 |
| An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03759288) | AstraZeneca | 2018-12-07 |
| Vedolizumab Post Op Study (NCT02834754) | Marc Schwartz | 2018-12-01 |
| Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs (NCT03729674) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2018-11-26 |
| Efficacy and Safety of TD-1473 in Crohn's Disease (NCT03635112) | Theravance Biopharma | 2018-11-19 |
| Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) (NCT03833596) | McMaster University | 2018-10-25 |
| Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (NCT03559517) | Shire | 2018-08-29 |
| Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) (NCT03196427) | Takeda | 2018-07-30 |
| Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (NCT03566823) | Shire | 2018-07-17 |
| An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease (NCT03599622) | Bristol-Myers Squibb | 2018-07-16 |
| One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study (NCT03662919) | Biogen | 2018-07-02 |
| Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients (NCT03566407) | Prometheus Laboratories | 2018-05-04 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03466411) | Janssen Research & Development, LLC | 2018-04-13 |
| Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease (NCT02843100) | Prof. Arie Levine | 2018-04-10 |
| A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease (NCT03478956) | Hoffmann-La Roche | 2018-03-27 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (NCT03345823) | AbbVie | 2018-03-21 |
| A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) (NCT03283085) | Shire | 2018-02-27 |
| Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease (NCT03395184) | Pfizer | 2018-02-02 |
| Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC (NCT03404557) | University Hospital, Clermont-Ferrand | 2018-01-18 |
| An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients (NCT07057856) | Second Affiliated Hospital of Wenzhou Medical University | 2018-01-01 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (NCT03104413) | AbbVie | 2017-12-18 |
| A Trial of Yoga in Pediatric Inflammatory Bowel Disease (NCT03338894) | Atlantic Health System | 2017-12-13 |
| A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (NCT03345849) | AbbVie | 2017-12-07 |
| Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease (NCT02559713) | Takeda | 2017-11-29 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy (NCT03345836) | AbbVie | 2017-11-29 |
| Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service (NCT03223012) | AbbVie | 2017-11-15 |
| Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) (NCT03138655) | Takeda | 2017-11-08 |
| An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab (NCT03167437) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-30 |
| A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions (NCT03017014) | AbbVie | 2017-09-26 |
| Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) (NCT03279081) | Tigenix S.A.U. | 2017-09-15 |
| Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease (NCT03397108) | The Hospital for Sick Children | 2017-08-31 |
| Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. (NCT03234907) | Takeda | 2017-08-03 |
| A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease (NCT03251118) | Target PharmaSolutions, Inc. | 2017-07-24 |
| Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain (NCT03155945) | Arena Pharmaceuticals | 2017-07-19 |
| Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases (NCT02735941) | Medical University of Graz | 2017-06-13 |
| Upper Gastrointestinal Lesions in Crohn's Disease (NCT03524144) | Sixth Affiliated Hospital, Sun Yat-sen University | 2017-06-01 |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03105128) | AbbVie | 2017-05-10 |
| GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) (NCT02994836) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 2017-04-21 |
| Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (NCT02914600) | Lakefront Biotherapeutics NV | 2017-03-17 |